Answers are grounded in this paper and cite their sources.
Observational cohort study reveals high survival and manageable toxicity with blinatumomab in pediatric B-ALL, suggesting immunotherapy is feasible in resource-constrained healthcare settings.
In 2025, blinatumomab was added to the WHO Essential Medicines List for Children for treating B-cell acute lymphoblastic leukemia (B-ALL), yet access remains limited in many low-and middle-income countries (LMICs). Consequently, real-world experience in these settings, particularly where access, supportive care, and delivery infrastructure differ substantially from those in high-income countries, remains poorly characterized. To evaluate the early clinical effectiveness and implementation challenges of blinatumomab administration for pediatric B-ALL in lower-middle-income countries, an observational cohort study was conducted at 6 pediatric oncology centers participating in a blinatumomab drug-access program in India, Pakistan, and Vietnam. A consecutive sample of 106 children aged 1-18 years with relapsed/refractory B-ALL (n = 60, 56.6%) or minimal residual disease (MRD) > 0.1% (n = 46, 43.4%) were treated with blinatumomab. Across 192 treatment cycles, 54 unplanned interruptions occurred, primarily due to adverse events. Severe (grade 3+) cytokine release syndrome occurred in 2 patients during cycle 1; severe neurotoxicity occurred in 4 patients in cycle 1 and 1 in cycle 2. Among 71 patients with follow-up data, 26 patients (36.6%) subsequently received a hematopoietic stem cell transplant (HSCT), including 14 for relapsed/refractory disease. Six-month EFS and OS were 61.5% ± 5.8% and 89.9% ± 3.6%, respectively, and 12-month EFS and OS were 58.1% ± 7.1% and 82.8% ± 5.5%, respectively. Survival did not differ significantly between patients who received an HSCT and those who did not. MRD-negative status after cycle 1 was associated with superior 12-month EFS (P < 0.0001) and OS (P = 0.0366). With implementation support, blinatumomab was safely and effectively delivered in pediatric referral centers in lower-middle-income countries, supporting strategies to broaden immunotherapy access globally.
No takes yet. Share an insight, caveat, or question.
Duffy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: